Harvey Investment Co. LLC Trims Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Harvey Investment Co. LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,493 shares of the company’s stock after selling 650 shares during the quarter. IDEXX Laboratories accounts for about 2.5% of Harvey Investment Co. LLC’s holdings, making the stock its 15th biggest position. Harvey Investment Co. LLC’s holdings in IDEXX Laboratories were worth $21,703,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $31,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after acquiring an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $37,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $460.56 on Friday. The company’s fifty day simple moving average is $427.59 and its 200-day simple moving average is $453.67. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a market cap of $37.72 billion, a PE ratio of 44.41, a P/E/G ratio of 3.64 and a beta of 1.37.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on IDXX shares. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $524.38.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.18% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.